Barclays raised the firm’s price target on Humana (HUM) to $245 from $234 and keeps an Equal Weight rating on the shares. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward “de-rated underperformers.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- UnitedHealth and Humana Mail-Order Pharmacies Tied to Higher Medicare Refill Costs
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- President Trump says he’ll meet with insurance companies on price cuts
- Consumers left in limbo as ACA subsidies are not renewed, WSJ says